Loading
AdaptHealth Corp. Stock: price and insider trades · United States
2 insiders bought €451k of shares over the last 90 days, the latest filed 14 Aug 2026.
AdaptHealth Corp.: what insiders have been doing
This page follows insider dealings at AdaptHealth Corp. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 35 filings were filed, from 19 insiders.
Open-market activity splits into 8 purchases totalling €7.4M and 2 sales totalling €138k; 4 insiders sit on the buying side and 2 insiders on the selling side. Netting one side against the other leaves €7.3M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €6.9M, bought by Cashin Richard M Jr and made public on 12 March 2026. The buyers include 3 senior executives.
Compared with its exchange (5,811 companies, median 19 filings), a count of 35 filings is above the norm. Since 2021, the database holds 29 purchases and 44 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 3.24 bn USD and net income at -70.8 m USD.
In all, 7 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 14 August 2026, which is 65 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
240
Thresholds
n/a
Buy Volume
€16M
29 ops. · all time
Sell Volume
€77M
44 ops. · all time
Who traded when
BuySaleDale B. Wolf4 buys1 sale
David Solomon Williams III2 sales
OEP VII GP, L.L.C.2 buys
RICHARD M. CASHIN Jr.2 buys
Schuster III Russell E.2 sales
Clemens Jason A1 sale
+2 other insiders
Since the insiders bought
- +10.0%Entry US$5.81 · Close 15 Oct 2026 US$6.39
- +13.1%Entry US$5.65 · Close 15 Oct 2026 US$6.39
- -15.9%Entry US$11.48 · Close at T+90 US$9.66
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate AdaptHealth Corp. Strong Buy (bullish), based on 7 analysts. Average price target: US$8.86.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,220 of 24,148 companies
43.4
score / 100
Value66
Quality21
FCF yld26%
Earn yld-8.3%
EV/EBITDA5.8x
ROE-15%
Gross mgn19%
Net mgn-2.2%
Debt/EBITDA4.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.25
Analyst consensus
7 analystsStrong buy
US$7.00Target US$8.86(+42%)US$10.00
Income statement
RevenueUS$3.2B
Gross profitUS$609.2M19% margin
EBITDAUS$472.5M15% margin
Net income-US$70.8M-6.8% margin
Valuation
PER (forward)-49.6x
P/Book0.6x
Beta1.42
Balance sheet & cash
Market capUS$850.3M
Total debtUS$1.9B
Free Cash FlowUS$219.4M
Debt / Equity149%
Profitability & ownership
ROE-15.2%
ROA2.3%
% insiders8.3%
% institutions100.3%
Last declaration on 11 September 2026
Declarations240 total
141,372 shares0Common StockSEC:0001104659-26-107061:0
20,000 shares@ US$6.300.016% mcap13.3% of flowCommon StockSEC:0001104659-26-097053:0
Canonical exit: 4 Nov 2026 (T+90)
20,000 shares@ US$6.370.017% mcap13.5% of flowCommon StockSEC:0001104659-26-093575:0
Canonical exit: 4 Nov 2026 (T+90)
20,000 shares@ US$5.860.015% mcap12.4% of flowCommon StockSEC:0001104659-26-093575:1
Canonical exit: 5 Nov 2026 (T+90)
23,500 shares@ US$6.380.019% mcap100.0% of flowCommon StockSEC:0001104659-26-093576:0
Canonical exit: 4 Nov 2026 (T+90)
11,275 shares@ US$10.440.016% mcap51.4% of flowCommonSEC144:0001959173-26-005003
18,999 sharesCommon StockSEC:0001104659-26-078281:0
18,999 sharesCommon StockSEC:0001104659-26-078238:0
6,070 sharesCommon StockSEC:0001104659-26-078238:1
18,999 sharesCommon StockSEC:0001104659-26-078240:0
18,999 sharesCommon StockSEC:0001104659-26-078257:0
18,999 sharesCommon StockSEC:0001104659-26-078262:0
18,999 sharesCommon StockSEC:0001104659-26-078264:0
18,999 sharesCommon StockSEC:0001104659-26-078285:0
18,999 sharesCommon StockSEC:0001104659-26-078268:0
11,275 shares@ US$10.060.015% mcap48.6% of flowCommon StockSEC:0001104659-26-070230:0
20,134 shares0Common StockSEC:0001104659-26-068272:0
58,203 shares@ US$10.330.081% mcap35.9% of flowCommon StockSEC:0001104659-26-050577:0
▲
Same trade as the filing by Richard M. Cashin Jr., counted once · View ↗
727 shares@ US$9.94170.0010% mcap0.1% of flowCommon StockSEC:0001193125-26-132703:0
Canonical exit: 17 Jun 2026 (T+90)
▲
Same trade as the filing by Richard M. Cashin Jr., counted once · View ↗
820,528 shares@ US$9.72871.06% mcap99.9% of flowCommon StockSEC:0001193125-26-132663:0
Canonical exit: 8 Jun 2026 (T+90)
727 shares@ US$9.94170.1% of flowCommon StockSEC:0001193125-26-120145:0
Canonical exit: 17 Jun 2026 (T+90)
89,451 shares@ US$4.3823.4% of flowCommon StockSEC:0001104659-26-028442:0
820,528 shares@ US$9.728799.9% of flowCommon StockSEC:0001193125-26-104760:0
Canonical exit: 8 Jun 2026 (T+90)
73,472 shares0Common StockSEC:0001104659-26-025412:0
8,000 shares@ US$8.967.4% of flowCommon StockSEC:0001104659-26-023001:0
Canonical exit: 28 May 2026 (T+90)
25 of 240 declarations
About AdaptHealth Corp.
AdaptHealth Corp. (ticker: AHCO) is a United States-listed healthcare company traded on the NASDAQ, not the NYSE. Headquartered in Conshohocken, Pennsylvania, United States, the company has built itself into a national player in home-based healthcare solutions, with a core focus on home medical equipment, medical supplies, and related services. Its business model is centered on supporting patients after hospital discharge or following a physician referral, helping extend care into the home while improving adherence, convenience, and overall cost efficiency. ([adapthealth.com](https://adapthealth.com/2026/02/24/adapthealth-corp-announces-fourth-quarter-and-full-year-2025-results-and-provides-2026-financial-guidance/?utm_source=openai))
AdaptHealth reports four business segments that align with its product categories: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. This structure gives the company exposure to several durable healthcare demand pools, including sleep apnea and respiratory therapy, diabetes care and glucose monitoring, and broader home wellness and care-at-home solutions. The company’s portfolio includes continuous glucose monitoring devices, insulin pumps, respiratory devices and supplies, and other home-based medical products and services. Management positions AdaptHealth as a nationwide network of trusted medical equipment providers, combining clinically focused products, technology, and patient support. ([adapthealth.com](https://adapthealth.com/investorrelations/corporate-profile/?utm_source=openai))
Read moreShow less
From a competitive standpoint, AdaptHealth operates in a highly fragmented but competitive market, facing national and regional rivals such as Owens & Minor, Lincare, Rotech, Cardinal Health, and Quipt Home Medical, among others. Its strategic edge lies in scale, geographic reach, and the ability to serve multiple product categories through a broad operational platform. As of year-end 2025, the company said it served approximately 4.3 million patients annually across 48 states, underscoring its broad U.S. footprint and national distribution network. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1725255/000162828025007740/ahco-20241231.htm?utm_source=openai))
Recent developments have centered on balance-sheet repair and operational simplification. In 2025, the company completed the sale of certain non-core infusion assets to help reduce debt, and in November 2025 S&P Global Ratings upgraded the issue-level rating on AdaptHealth’s senior unsecured debt. In February 2026, AdaptHealth reported full-year 2025 results and issued 2026 guidance, highlighting operating cash flow growth, record patient census in several categories, and the acquisition of a leading HME provider in Hawaii, which expanded the company’s footprint to its 48th state. For investors, AHCO is therefore a healthcare-at-home name with meaningful scale and structural tailwinds, but one that remains sensitive to reimbursement dynamics, patient volumes, and execution on its capital structure. ([adapthealth.com](https://adapthealth.com/blogs/latest-news/adapthealth-corp-closes-transaction-to-dispose-of-certain-home-infusion-assets-and-reduces-debt?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
